Dimethyl Fumarate Protects Retinal Pigment Epithelium from Blue Light-Induced Oxidative Damage via the Nrf2 Pathway

Dimethyl Fumarate Protects Retinal Pigment Epithelium from Blue Light-Induced Oxidative Damage via the Nrf2 Pathway

The purpose of this study is to investigate the protective effect of dimethyl fumarate (DMF), the methyl-ester of fumaric acid, against blue-light (BL) exposure in retinal pigment epithelial (RPE) cells. ARPE-19 cells, a human RPE cell line, were cultured with DMF followed by exposure to BL. Reactiv...

Full description

Bibliographic Details
Main Authors:	Hideyuki Shimizu, Kei Takayama, Kazuhisa Yamada, Ayana Suzumura, Tomohito Sato, Yoshiaki Nishio, Masataka Ito, Hiroaki Ushida, Koji M Nishiguchi, Masaru Takeuchi, Hiroki Kaneko
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	Antioxidants
Subjects:	dimethyl fumarate blue-light nuclear factor (erythroid-derived)-like 2 retinal pigment epithelium oxidative stress NRF2 pathway
Online Access:	https://www.mdpi.com/2076-3921/12/1/45

Similar Items

Patients monitoring during treatment with Dimethyl fumarate (ORP-23)
by: Ali Yousefi Pour
Published: (2023-01-01)

Effect and mechanism of dimethyl fumarate on septic cardiomyopathy in mice
by: MIN Weixiang, et al.
Published: (2022-11-01)

Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19
by: Cara A. Timpani, et al.
Published: (2020-12-01)

The Challenge of Dimethyl Fumarate Repurposing in Eye Pathologies
by: Federico Manai, et al.
Published: (2022-12-01)

The Antineoplastic Effect of Dimethyl Fumarate on Virus-Negative Merkel Cell Carcinoma Cell Lines: Preliminary Results
by: Thilo Gambichler, et al.
Published: (2023-01-01)

Dimethyl Fumarate as Potential Treatment for Alzheimer’s Disease: Rationale and Clinical Trial Design
by: Robert Sharkus, et al.
Published: (2023-05-01)

Dimethyl fumarate reduces inflammation in chronic active multiple sclerosis lesions
by: Zinger, Nicole, et al.
Published: (2023)

Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study
by: Laura Gnesotto, et al.
Published: (2023-03-01)

Dimethyl Fumarate Triggers the Antioxidant Defense System in Human Retinal Endothelial Cells through Nrf2 Activation
by: Federico Manai, et al.
Published: (2022-09-01)

Dimethyl fumarate improves cognitive impairment and neuroinflammation in mice with Alzheimer’s disease
by: Ting Wang, et al.
Published: (2024-02-01)

Dimethyl fumarate for treating Papillon–Lefèvre syndrome
by: Abdullah Al-Omair, MD, et al.
Published: (2023-01-01)

Drug-Repurposing Strategy for Dimethyl Fumarate
by: Salvatore Giunta, et al.
Published: (2023-07-01)

Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?
by: Stephanie Kourakis, et al.
Published: (2020-10-01)

Novel potential pharmacological applications of dimethyl fumarate—an overview and update
by: Giorgia Bresciani, et al.
Published: (2023-09-01)

Utilization of dimethyl fumarate and related molecules for treatment of multiple sclerosis, cancer, and other diseases
by: Azzam Maghazachi, et al.
Published: (2016-07-01)

A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles
by: Francisco Javier García-Fernández, et al.
Published: (2021-02-01)

Prevention of Autoimmune Diabetes in NOD Mice by Dimethyl Fumarate
by: Shiri Li, et al.
Published: (2021-01-01)

Dimethyl Fumarate Alleviates Dextran Sulfate Sodium-Induced Colitis, through the Activation of Nrf2-Mediated Antioxidant and Anti-inflammatory Pathways
by: Shiri Li, et al.
Published: (2020-04-01)

Thyroid Disorders in Patients Treated with Dimethyl Fumarate for Multiple Sclerosis: A Retrospective Observational Study
by: Cédric O. Renaud, et al.
Published: (2022-05-01)

Repurposing dimethyl fumarate for gastric ulcer and ulcerative colitis: Evidence of local efficacy without systemic side effect
by: Vishal Patel, et al.
Published: (2022-12-01)

The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
by: Roberto De Masi, et al.
Published: (2021-01-01)

Dimethyl Fumarate Used as an Effective Treatment for Granuloma Annulare Disseminatum: An Immunohistochemical Case Study
by: Max Gabutti, et al.
Published: (2023-08-01)

USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS
by: V. R. Mkrtchyan, et al.
Published: (2016-12-01)

Repurposing Dimethyl Fumarate for Cardiovascular Diseases: Pharmacological Effects, Molecular Mechanisms, and Therapeutic Promise
by: Shilu Deepa Thomas, et al.
Published: (2022-04-01)

Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
by: Angel Chinea, et al.
Published: (2020-05-01)

Repurposing dimethyl fumarate as an antiepileptogenic and disease-modifying treatment for drug-resistant epilepsy
by: Sereen Sandouka, et al.
Published: (2023-11-01)

Dimethyl fumarate attenuates reactive microglia and long-term memory deficits following systemic immune challenge
by: Hallel C. Paraiso, et al.
Published: (2018-03-01)

Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
by: Mitzi J. Williams, et al.
Published: (2020-05-01)

Exploring the Use of Dimethyl Fumarate as Microglia Modulator for Neurodegenerative Diseases Treatment
by: Maria Rosito, et al.
Published: (2020-08-01)

Glucose-Impaired Corneal Re-Epithelialization Is Promoted by a Novel Derivate of Dimethyl Fumarate
by: Giovanni Giurdanella, et al.
Published: (2021-05-01)

Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis
by: Kosuke Kato, et al.
Published: (2022-02-01)

Short-term exposure to dimethyl fumarate (DMF) inhibits LPS-induced IκBζ expression in macrophages
by: Yong Zhang, et al.
Published: (2023-02-01)

New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate
by: Paolinelli Matteo, et al.
Published: (2022-12-01)

Drug repurposing: Clemastine fumarate and neurodegeneration
by: Jiahui Zhu, et al.
Published: (2023-01-01)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
by: Aliya Jaber, et al.
Published: (2023-02-01)

Novel Heme Oxygenase-1 (HO-1) Inducers Based on Dimethyl Fumarate Structure
by: Valeria Sorrenti, et al.
Published: (2020-12-01)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
by: Martin Diebold, et al.
Published: (2022-12-01)

Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM
by: Mitzi J. Williams, et al.
Published: (2023-06-01)

Dimethyl fumarate alleviates allergic asthma by strengthening the Nrf2 signaling pathway in regulatory T cells
by: Yanhong Cen, et al.
Published: (2024-04-01)

Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies
by: Lilyana Amezcua, et al.
Published: (2023-04-01)